Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Top Cited Papers
- 1 June 2016
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 16 (6) , 685-697
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
This publication has 12 references indexed in Scilit:
- Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver TransplantationClinical Gastroenterology and Hepatology, 2015
- EASL Recommendations on Treatment of Hepatitis C 2015Journal of Hepatology, 2015
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)The Lancet Infectious Diseases, 2015
- Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver TransplantationGastroenterology, 2015
- Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label StudyGastroenterology, 2015
- Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantationHepatology, 2014
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJAMA, 2012
- The natural history of hepatitis C cirrhosis after liver transplantationLiver Transplantation, 2009
- Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis BLiver Transplantation, 2007
- The Survival Benefit of Liver TransplantationAmerican Journal of Transplantation, 2004